CLINICAL RESEARCH
Comparison of moxifloxacin-based therapies and standard bismuth-based quadruple therapy for first-line treatment of Helicobacter pylori infection
 
More details
Hide details
 
Submission date: 2018-05-28
 
 
Final revision date: 2018-07-14
 
 
Acceptance date: 2018-07-31
 
 
Publication date: 2018-10-08
 
 
Arch Med Sci Civil Dis 2018;3(1):81-86
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Helicobacter pylori antibiotic resistance continues to be an important issue for decisions regarding eradication treatment. The aim of our study was to compare the efficacy of two bismuth-containing quadruple regimens: one including moxifloxacin, and the other including metronidazole, tetracycline and triple therapy with moxifloxacin as a first-line regimen.

Material and methods:
A total of 332 patients received three different regimens: (a) moxifloxacin-containing bismuth quadruple therapy, BMAR (bismuth subsalicylate 562 mg, BID, moxifloxacin 500 mg QD, amoxicillin 1 g, BID, rabeprazole 20 mg, BID); (b) standard bismuth quadruple therapy, BTMR (bismuth subsalicylate 562 mg, BID, tetracycline 500 mg, QID, metronidazole 500 mg, TID, rabeprazole 20 mg, BID, for 2 weeks); or (c) moxifloxacin-containing triple therapy, MAR (moxifloxacin 500 mg, QD, amoxicillin 1 g, BID and rabeprazole 20 mg, BID).

Results:
The eradication rates of the three groups using ITT analysis were BMAR 93.6%, BTMR 78.4% and MAR 90.8%. Rates were 98.9%, 87% and 99.1%, respectively, using PP analysis. The eradication rate was significantly higher in the BMAR group than in the other groups based on ITT analysis (p < 0.001). There was no significant difference between the BMAR and MAR groups based on PP analysis (p > 0.05); however, the eradication rate was significantly higher in both of the groups than in the BTMR group (p < 0.001).

Conclusions:
Moxifloxacin-containing regimens are efficacious choices for first-line therapy of H. pylori eradication. Adding bismuth therapy to moxifloxacin-based therapies only increases adverse events without increasing the eradication rate.

 
REFERENCES (21)
1.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence consensus report. Gut 2012; 61: 646-64.
 
2.
Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015; 136: 487-90.
 
3.
Kim TJ, Lee H, Kang M, et al. Helicobacter pylori is associated with dyslipidemia but not with other risk factors of cardiovascular disease. Sci Rep 2016; 6: 38015.
 
4.
Kocazeybek B, Tokman HB. Prevalence of primary antimicrobial resistance of H. pylori in Turkey: a systematic review. Helicobacter 2016; 21: 251-60.
 
5.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6-30.
 
6.
Zhang G, Zou J, Liu F, et al. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res 2013; 46: 607-13.
 
7.
Lim JH, Lee DH, Lee ST, et al. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection. World J Gastroenterol 2015; 21: 13124-31.
 
8.
Kwon S, Lee DH, Kang JB, et al. The efficacy of moxifloxacin containing triple therapy after hybrid therapy failure in Helicobacter pylori eradication. Korean J Gastroenterol 2017; 70: 72-80.
 
9.
Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 527532.
 
10.
Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 21: 1241-7.
 
11.
Wenzhen Y, Kehu Y, Bin M, et al. Moxifloxacin-based triple therapy versus clarithyomycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. Intern Med 2009; 48: 2069-76.
 
12.
Rakici H, Ayaz T, Akdogan RA, Bedir R. Comparison of levofloxacin- and moxifloxacin based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. Digestion 2014; 90: 261-4.
 
13.
Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Dig Liver Dis 2010; 42: 110-4.
 
14.
Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361-70.
 
15.
Whitehead MW, Phillips RH, Sieniawska CE, et al. Double-blind comparison of absorbable colloidal bismuth subcitrate and nonabsorbable bismuth subnitrate in the eradication of Helicobacter pylori and the relief of nonulcer dyspepsia. Helicobacter 2000; 5: 169-175.
 
16.
Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514-33.
 
17.
Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-10.
 
18.
Glocker, E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51: 346349.
 
19.
Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol 2011; 4: 103-14.
 
20.
Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect 2018; 24: 780.e5-e8.
 
21.
Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal 2018; 32: e22339.
 
ISSN:2451-0637
Journals System - logo
Scroll to top